NAD+ by Dragon Pharma

Dragon Pharma Original Formula

NAD+

Nicotinamide Adenine Dinucleotide500 mg vial
Class Essential Coenzyme
Primary Role Sirtuin / PARP Substrate
Route Advantage Injectable = Direct Bioavailability
Suppression None (HPG)
Reconstitution Bacteriostatic Water
Form Intravenous / Subcutaneous Vial
Availability: In Stock
$80.00
Quantity
Shipping
Wishlist

NAD+ 500mg — Injectable Nicotinamide Adenine Dinucleotide by Dragon Pharma

NAD+ (Nicotinamide Adenine Dinucleotide) is Dragon Pharma's injectable formulation of the fundamental cellular coenzyme at 500mg per vial — not a peptide or a hormone, but the most essential redox molecule in cellular metabolism, required as a substrate by sirtuins (epigenetic regulatory proteins), PARP (DNA repair enzymes), and the mitochondrial electron transport chain. NAD+ declines approximately 50% between ages 40-60 in most tissues. Injectable NAD+ delivers the coenzyme directly to systemic circulation, bypassing the metabolic conversion steps required by oral NAD+ precursors (NMN, NR).

Also searched as: NAD+ injection, injectable NAD, Nicotinamide Adenine Dinucleotide, NAD+ IV, NAD Dragon Pharma.

Why Injectable NAD+ Instead of Oral Precursors (NMN/NR)

Understanding why the injectable route matters requires understanding the pharmacokinetics of NAD+ supplementation:

  • NAD+ itself is a large, charged molecule — it does not efficiently cross cell membranes or intestinal walls when taken orally. Oral NAD+ is substantially degraded in the gut before absorption and what reaches systemic circulation is minimal
  • Oral NAD+ supplementation therefore uses precursors: NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are smaller molecules that are absorbed orally and converted to NAD+ intracellularly. These are legitimate approaches but involve conversion steps, tissue-specific uptake efficiency, and significant inter-individual variability
  • Injectable NAD+ bypasses all conversion steps — it delivers the final product (NAD+ itself) directly to systemic circulation. Tissues then take up NAD+ from blood and phosphorylate it intracellularly to the forms needed for metabolic function
  • IV NAD+ administration (as used in clinical addiction and anti-aging protocols) produces rapid, measurable elevation of blood NAD+ levels and subjective effects (mental clarity, energy) within hours — effects that oral precursors take days to weeks to produce. Subcutaneous injection provides a middle ground between IV speed and convenience

The Three Key NAD+ Mechanisms

NAD+ is not a single-function molecule — it drives three distinct and critical cellular processes:

  • 1. Sirtuins (SIRT1-7) — Epigenetic Regulation and Longevity
    Sirtuins are a family of seven NAD+-dependent deacetylase enzymes that regulate gene expression by removing acetyl groups from histones and other proteins. They are central to: DNA repair, inflammation reduction, metabolic regulation, circadian rhythm maintenance, and cellular stress response. SIRT1 and SIRT3 are particularly active in response to caloric restriction and exercise — the same interventions that extend lifespan in animal models. All seven sirtuins require NAD+ as a co-substrate — they cannot function without it. As NAD+ declines with age, sirtuin activity falls correspondingly
  • 2. PARP Enzymes — DNA Damage Response
    PARP (Poly ADP-Ribose Polymerase) enzymes detect and repair DNA strand breaks — responding to the thousands of DNA damage events that occur in each cell daily. PARP enzymes consume NAD+ as their energy source during repair — each repair cycle depletes cellular NAD+ significantly. With aging and increasing oxidative stress (including from intense exercise and AAS use), PARP is activated more frequently, consuming more NAD+ and contributing to NAD+ depletion. Providing NAD+ directly supports PARP's ability to sustain DNA repair without depleting the cellular NAD+ pool for other functions
  • 3. Electron Transport Chain — Mitochondrial Energy Production
    NAD+ is the primary electron carrier in mitochondrial energy production — in its reduced form (NADH), it carries electrons to Complex I of the electron transport chain, driving ATP synthesis. The NAD+/NADH ratio is a fundamental regulator of metabolic rate and mitochondrial efficiency. Elevating the NAD+ pool shifts the NAD+/NADH ratio toward oxidised NAD+, favouring increased mitochondrial activity, fatty acid oxidation and energy production

CD38 — The NAD+ Destroyer That Increases With Age

A specific mechanism that most competitor content omits entirely:

  • CD38 is an enzyme that is the primary consumer of NAD+ in aged tissues — it is an NADase (NAD-consuming enzyme) expressed on immune cells and other tissues
  • CD38 expression increases dramatically with age and inflammation — it is upregulated by the same inflammatory signals that characterise the "inflammaging" phenomenon of aging
  • In aged mice, CD38 knockout (removing CD38) prevents age-related NAD+ decline and maintains sirtuin activity at youthful levels — confirming CD38 as the primary driver of age-related NAD+ depletion
  • For practical supplementation: the same factors that elevate CD38 (inflammation, oxidative stress) are present during intense AAS cycles. Providing injectable NAD+ directly replenishes the pool that CD38 is consuming — a continuous resupply strategy against the NAD+-destroying enzyme

NAD+ and Exercise — The AAS Context

The performance-specific relevance of NAD+ supplementation:

  • Intense exercise — particularly eccentric loading and muscle damage — produces significant oxidative stress that activates PARP, consuming NAD+. Post-exercise cellular NAD+ depletion is measurable and recovery of NAD+ levels takes 12-48 hours
  • AAS cycles, particularly those involving high training volumes and the additional oxidative stress of 17-AA oral compounds, place above-average PARP activation demand on cells — accelerating NAD+ consumption
  • Sirtuin activity during recovery is NAD+-dependent — SIRT1 and SIRT3 are involved in the muscular adaptation response to exercise and the mitochondrial biogenesis that follows training. Maintaining NAD+ levels supports this adaptation process
  • NAD+ infusions are used clinically in post-operative recovery contexts to support cellular energy production during healing — the same principle applies to post-training or post-competition recovery

Effects and Benefits

  • Direct NAD+ delivery — bypasses oral precursor conversion variability; immediate systemic elevation
  • Sirtuin activation — all seven sirtuins are NAD+-dependent; elevated NAD+ restores sirtuin function toward youthful activity levels
  • DNA repair support — PARP enzyme function is sustained without depleting the cellular NAD+ pool
  • Mitochondrial energy production enhancement — improved NAD+/NADH ratio supports electron transport chain efficiency
  • Mental clarity and energy — rapid subjective effects after IV/subcutaneous administration; reported consistently in clinical NAD+ infusion data
  • No testosterone suppression — no PCT required

Dosage and Administration

Protocol Dose Route Frequency
Recovery / acute support 250–500 mg Subcutaneous or slow IV Daily for 3–5 days; then weekly maintenance
Longevity maintenance 250 mg Subcutaneous Weekly or biweekly

At 500mg per vial, one full vial is an acute dose; 250mg (half vial) for maintenance. IV administration produces the fastest and most pronounced effects but requires appropriate clinical setting and slow infusion (nausea, flushing and chest tightness are common with fast IV NAD+ — always infuse slowly over 1-2 hours if given IV). Subcutaneous injection is safer and more practical for self-administration. Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated at 2-8°C for up to 28 days.

Side Effects

  • Flushing, warmth and nausea — common during or after administration, particularly IV. Subcutaneous route reduces but does not eliminate these effects. Generally transient and dose-related
  • Chest tightness/pressure — reported with rapid IV infusion; always infuse slowly if administering IV; does not typically occur with subcutaneous injection
  • No hormonal side effects — no testosterone, estrogen or HPG axis interaction

Stacking Context

  • MOTS-c — mitochondrial-derived peptide activating AMPK alongside NAD+'s sirtuin and electron transport chain support; complementary mitochondrial enhancement from different angles
  • Epitalon — telomerase activation alongside NAD+'s DNA repair support through PARP; both address different aspects of cellular longevity maintenance
  • BPC-157 — tissue repair peptide; BPC-157's local repair combined with NAD+'s systemic cellular energy and DNA repair support for comprehensive recovery

"Injectable NAD+ delivers the coenzyme directly — no conversion from precursors, no gut absorption limitation. Sirtuins, PARP and the electron transport chain all require NAD+ to function, and all are compromised when NAD+ declines with age or is depleted by intense exercise and oxidative stress."

Storage and Handling

Store NAD+ at room temperature or refrigerated before reconstitution. After reconstituting with bacteriostatic water, store refrigerated at 2-8°C and use within 28 days. NAD+ is light-sensitive — protect from direct light after reconstitution.

Please log in to write review.

Oral NAD+ itself is poorly absorbed — it is a large, charged molecule degraded in the gut before meaningful systemic absorption. Oral supplementation therefore uses precursors: NMN and NR are smaller molecules absorbed orally and converted to NAD+ intracellularly through multiple enzymatic steps. This conversion is efficient in some tissues but variable across individuals and cell types. Injectable NAD+ delivers the final product directly to systemic circulation — bypassing conversion steps and gut absorption limitations. The result is more rapid, more predictable and more complete NAD+ elevation than oral precursor approaches.

Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylase enzymes that regulate gene expression by removing acetyl groups from histones and other proteins. They mediate many of the longevity benefits associated with caloric restriction and exercise — regulating DNA repair, inflammation suppression, mitochondrial biogenesis and metabolic efficiency. Critically, sirtuins use NAD+ as an obligate co-substrate — each deacetylation reaction consumes NAD+. As cellular NAD+ declines with age, sirtuin activity falls correspondingly, contributing to the hallmarks of aging at the gene expression level.

CD38 is an NADase enzyme — it breaks down NAD+ — and its expression increases dramatically with age and inflammation. Research in aged mice showed that CD38 knockout (genetic removal) prevented age-related NAD+ decline and maintained youthful sirtuin activity. CD38 is the primary driver of NAD+ depletion in aged tissues, outcompeting the biosynthetic pathways that produce NAD+. Injectable NAD+ directly replenishes the pool that CD38 is chronically consuming — a supply strategy against the enzyme that causes age-related depletion.

Two primary causes: CD38 (the NADase enzyme, see above) increases with age and inflammation, consuming NAD+ faster than cells can synthesise it. PARP enzymes — which repair DNA damage — also consume NAD+ as their energy substrate. With aging and increasing oxidative stress (including from intense exercise and 17-AA oral AAS use), PARP is activated more frequently, depleting NAD+ further. The combined effect — more consumption (CD38, PARP) and reduced synthesis — produces the ~50% NAD+ decline seen between ages 40-60 in most tissues.

Flushing, warmth and nausea are the most common — particularly with IV administration. These result from the rapid systemic NAD+ elevation and are dose and infusion rate-dependent. Always infuse IV NAD+ slowly over 1-2 hours; fast bolus IV injection causes pronounced chest tightness and pressure that is alarming though not typically dangerous. Subcutaneous injection produces milder flush and nausea effects than IV. Side effects are transient and resolve within 30-60 minutes of administration for most users.

No — NAD+ is an endogenous coenzyme with no interaction with androgen receptors, testosterone, LH, FSH or the HPG axis. It can be used during any phase of an AAS cycle or PCT without concern for hormonal interference. The performance relevance is specifically in cellular recovery: NAD+'s support for sirtuin-mediated gene expression and PARP-driven DNA repair enhances the cellular adaptation and recovery processes that AAS training is designed to stimulate.